Why carry out this study?

There is currently limited information available from observational studies on the specific clinical and economic burden of mild-to-moderate atopic dermatitis (AD), which represents approximately 90% of all AD cases.

This study aimed to assess the burden of mild-to-moderate AD in the UK.

What was learned from the study?

Mild-to-moderate AD patients had a higher comorbidity burden, healthcare resource utilisation (HCRU) and costs compared with matched non-AD controls in the UK primary care setting.

A cost-of-illness model projected total HCRU and drug excess costs of €462.99M cumulatively for the 5-year time horizon at the UK population level.

Productivity burden and comorbidities were found to have considerable impact on the economic burden of mild-to-moderate AD.